GMXRX Mutual Fund

NAV$16.67

Fund Essentials - as of Jan 31, 2026

Net Assets
$24M
Expense Ratio
1.00%
Dividend Yield (Current)
11.20%
Holdings
405
Inception Date
Mar 9, 2007
Fund Family
Nationwide
Investment Style
PRO
Asset Class
PRO
Legal Structure
PRO
Dividend Frequency
Quarterly

Performance

YTD+13.48%
1 Year+24.74%
3 Year+14.27%
5 Year+8.00%
10 Year+10.47%

Asset Allocation

Stocks: 94.16%
Bonds: 5.85%

Price Chart (6M)

View Full Chart →

Top Holdings

View All →
TickerNameWeight
-Borr Drilling Ltd.2.49%
-Treasury Repurchase Agreement1.74%
-Treasury Repurchase Agreement1.09%
CIENCiena Corp1.06%
COHRCoherent Corp.1.00%
Top 10 Concentration: 10.97%Report Date: Jan 31, 2026
Download all 405 holdings for GMXRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
11.20%
Frequency
Quarterly
Latest Distribution
$0.02
-

Peer Comparison

Benchmark
PRO
Peer outperformance: PRO
Category rank: PRO
This Mutual Fund
PRO
Peer Avg
PRO
See how GMXRX ranks against its peers
Category rank, peer-average returns and outperformance, updated daily.
$49$29/mo
Claim the $29 launch price
First 500 subscribers, then $49/mo. Cancel anytime. From MarketXLS, trusted since 2014.

GMXRX Mutual Fund Overview

GMXRX Mutual Fund (Nationwide Mid Cap Market Index Fund Class R) is managed by Nationwide with $23.9M in net assets. GMXRX expense ratio is 1.00%, holding 405 positions across sectors including Industrials, Financials, Information Technology. Inception date: 2007-03-09.

GMXRX performance shows a YTD return of 13.48%. The 1-year return is 24.74% and the 5-year return is 8.00%. GMXRX dividend yield stands at 11.20%, paid quarterly.

GMXRX top holdings include Borr Drilling Ltd. (2.5%), Treasury Repurchase Agreement (1.7%), Treasury Repurchase Agreement (1.1%), Ciena Corp (1.1%), Coherent Corp. (1.0%). View all GMXRX holdings, sector breakdown, or dividend history.

GMXRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. GMXRX alternatives are available via the screener, along with tax-loss harvesting opportunities.